Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 3
1973 10
1974 16
1975 28
1976 25
1977 41
1978 31
1979 35
1980 65
1981 61
1982 41
1983 63
1984 42
1985 58
1986 43
1987 92
1988 65
1989 64
1990 54
1991 44
1992 49
1993 49
1994 52
1995 37
1996 32
1997 24
1998 33
1999 38
2000 42
2001 27
2002 41
2003 38
2004 29
2005 40
2006 28
2007 44
2008 35
2009 36
2010 48
2011 47
2012 51
2013 56
2014 54
2015 66
2016 77
2017 79
2018 98
2019 93
2020 157
2021 142
2022 173
2023 195
2024 88

Text availability

Article attribute

Article type

Publication date

Search Results

2,757 results

Results by year

Filters applied: . Clear all
Page 1
Oral minoxidil treatment for hair loss: A review of efficacy and safety.
Randolph M, Tosti A. Randolph M, et al. J Am Acad Dermatol. 2021 Mar;84(3):737-746. doi: 10.1016/j.jaad.2020.06.1009. Epub 2020 Jul 2. J Am Acad Dermatol. 2021. PMID: 32622136 Review.
OBJECTIVE: In recent years, oral minoxidil at low dose has been proposed as a safe alternative. This study reviewed articles in which oral minoxidil was used to treat hair loss to determine its efficacy and safety as an alternative to topical minoxidil. METHO …
OBJECTIVE: In recent years, oral minoxidil at low dose has been proposed as a safe alternative. This study reviewed articles in which …
Minoxidil in the treatment of androgenetic alopecia.
Goren A, Naccarato T. Goren A, et al. Dermatol Ther. 2018 Sep;31(5):e12686. doi: 10.1111/dth.12686. Epub 2018 Aug 28. Dermatol Ther. 2018. PMID: 30155952 Review.
In the US, minoxidil is approved over-the-counter (OTC) at a maximum concentration of 5%. In this review, we summarize the findings of the pivotal studies used in support of the drug's approval as well as recent discoveries and novel developments in the use of minoxidil
In the US, minoxidil is approved over-the-counter (OTC) at a maximum concentration of 5%. In this review, we summarize the findings o …
Minoxidil and its use in hair disorders: a review.
Suchonwanit P, Thammarucha S, Leerunyakul K. Suchonwanit P, et al. Drug Des Devel Ther. 2019 Aug 9;13:2777-2786. doi: 10.2147/DDDT.S214907. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31496654 Free PMC article. Review.
To date, topical minoxidil is the mainstay treatment for androgenetic alopecia and is used as an off-label treatment for other hair loss conditions. Despite its widespread application, the exact mechanism of action of minoxidil is still not fully understood. In this …
To date, topical minoxidil is the mainstay treatment for androgenetic alopecia and is used as an off-label treatment for other hair l …
Female-pattern hair loss: therapeutic update.
Müller Ramos P, Melo DF, Radwanski H, de Almeida RFC, Miot HA. Müller Ramos P, et al. An Bras Dermatol. 2023 Jul-Aug;98(4):506-519. doi: 10.1016/j.abd.2022.09.006. Epub 2023 Mar 30. An Bras Dermatol. 2023. PMID: 37003900 Free PMC article. Review.
There is also a lack of randomized, controlled studies with longitudinal follow-up, using objective outcomes and exploring the performance of the available treatments and their combinations. Topical minoxidil, which has been used to treat female pattern hair loss since the …
There is also a lack of randomized, controlled studies with longitudinal follow-up, using objective outcomes and exploring the performance o …
5% Minoxidil: treatment for female pattern hair loss.
Gupta AK, Foley KA. Gupta AK, et al. Skin Therapy Lett. 2014 Nov-Dec;19(6):5-7. Skin Therapy Lett. 2014. PMID: 25807073 Free article. Review.
Minoxidil is a Health Canada and US FDA-approved medication for hair loss in men and women. While 5% minoxidil foam has been approved for men since 2006, Health Canada and the FDA only approved 5% minoxidil foam for female pattern hair loss (FPHL) in 2014. ..
Minoxidil is a Health Canada and US FDA-approved medication for hair loss in men and women. While 5% minoxidil foam has been a
Natural Compounds Used for Treating Hair Loss.
Gasmi A, Mujawdiya PK, Beley N, Shanaida M, Lysiuk R, Lenchyk L, Noor S, Muhammad A, Strus O, Piscopo S, Komisarenko A, Fedorovska M, Bjørklund G. Gasmi A, et al. Curr Pharm Des. 2023;29(16):1231-1244. doi: 10.2174/1381612829666230505100147. Curr Pharm Des. 2023. PMID: 37151166 Review.
Various treatments for hair loss, including both synthetic drugs, such as minoxidil and finasteride, or medicinal herbs, have been approved by the Food and Drug Administration. ...
Various treatments for hair loss, including both synthetic drugs, such as minoxidil and finasteride, or medicinal herbs, have been ap …
Off-Label Use of Topical Minoxidil in Alopecia: A Review.
Stoehr JR, Choi JN, Colavincenzo M, Vanderweil S. Stoehr JR, et al. Am J Clin Dermatol. 2019 Apr;20(2):237-250. doi: 10.1007/s40257-018-0409-y. Am J Clin Dermatol. 2019. PMID: 30604379 Review.
Topical minoxidil is a well-known and often-utilized drug in dermatological practice for the treatment of alopecia. ...For others, such as eyebrow hypotrichosis, monilethrix, early traction alopecia, and CIA, there is more support for the efficacy of minoxidil. Alth …
Topical minoxidil is a well-known and often-utilized drug in dermatological practice for the treatment of alopecia. ...For others, su …
Interventions for female pattern hair loss.
van Zuuren EJ, Fedorowicz Z, Schoones J. van Zuuren EJ, et al. Cochrane Database Syst Rev. 2016 May 26;2016(5):CD007628. doi: 10.1002/14651858.CD007628.pub4. Cochrane Database Syst Rev. 2016. PMID: 27225981 Free PMC article. Review.
There were 40/407 adverse events in the twice daily minoxidil 2% group versus 28/320 in the placebo group (RR 1.24, 95% CI 0.82 to 1.87; low quality evidence). ...Furthermore, there was no difference in effect between the minoxidil 2% and 5% with the quality of evid …
There were 40/407 adverse events in the twice daily minoxidil 2% group versus 28/320 in the placebo group (RR 1.24, 95% CI 0.82 to 1. …
Minoxidil use in dermatology, side effects and recent patents.
Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Rossi A, et al. Recent Pat Inflamm Allergy Drug Discov. 2012 May;6(2):130-6. doi: 10.2174/187221312800166859. Recent Pat Inflamm Allergy Drug Discov. 2012. PMID: 22409453 Review.
Minoxidil, a vasodilator medication known for its ability to slow or stop hair loss and promote hair regrowth, was first introduced, exclusively as an oral drug, to treat high blood pressure. ...There have been cases of allergic reactions to the nonactive ingredient propyl
Minoxidil, a vasodilator medication known for its ability to slow or stop hair loss and promote hair regrowth, was first introduced,
2,757 results